Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …

Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

Background Given the projected trends in population ageing and population growth, the
number of people with dementia is expected to increase. In addition, strong evidence has …

Background Neurological disorders account for a large and increasing health burden
worldwide, as shown in the Global Burden of Diseases (GBD) Study 2016. Unpacking how …

Importance Reliable prevalence estimates are lacking for young-onset dementia (YOD), in
which symptoms of dementia start before the age of 65 years. Such estimates are needed for …

Alzheimer's disease (AD) is the most common cause of dementia. The pathophysiology of
this disease is characterized by the accumulation of amyloid-β, leading to the formation of …

Disease-modifying treatment strategies for Alzheimer disease (AD) are still under extensive
research. Nowadays, only symptomatic treatments exist for this disease, all trying to …

China has the largest population of patients with dementia in the world, imposing a heavy
burden on the public and health care systems. More than 100 epidemiological studies on …

Alzheimer's disease (AD) is highly heritable and recent studies have identified over 20
disease-associated genomic loci. Yet these only explain a small proportion of the genetic …

Importance There are currently no proven treatments to reduce the risk of mild cognitive
impairment and dementia. Objective To evaluate the effect of intensive blood pressure …